A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-designed, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PK101 Compared With PK101-002 in Patients With Knee Osteoarthritis
Latest Information Update: 08 Sep 2023
At a glance
- Drugs PK 101 (Primary) ; PK101-002
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors PMG Pharm Co Ltd
- 15 Sep 2021 Status changed from not yet recruiting to recruiting.
- 28 Apr 2021 New trial record